Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9123397 | 0.85 | NPSR1 (0.56) | ALDH1A1KDM4ESMN1; SMN2NPSR1HTT | |
| SCHEMBL7262181 | 0.84 | KDM4E (0.47) | ALDH1A1KDM4ESMN1; SMN2HTTHPGD | |
| SCHEMBL7795191 | 0.82 | ALDH1A1 (0.66) | ALDH1A1KDM4ESMN1; SMN2NPSR1HTT | |
| SCHEMBL12839869 | 0.81 | NPSR1 (0.63) | ALDH1A1KDM4ESMN1; SMN2NPSR1HTT | |
| SCHEMBL2059355 | 0.79 | CSNK2A2 (0.49) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL4364423 | 0.78 | PTGDR2 (0.46) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL3609276 | 0.78 | L3MBTL1 (0.54) | ALDH1A1KDM4ESMN1; SMN2NPSR1MEN1 | |
| SCHEMBL21254300 | 0.78 | KDM4E (0.43) | ALDH1A1KDM4ESMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL3064143 | 0.78 | TSHR (0.70) | ALDH1A1KDM4ESMN1; SMN2HTTMEN1 | |
| SCHEMBL2113005 | 0.78 | PTGDR2 (0.64) | ALDH1A1KDM4ESMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4240722-A1 | OXINDOLES AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | claimed |
| WO-2022099066-A1 | OXINDOLES AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | claimed |
| CN-116802176-A | Oxindoles and methods of use thereof | 阿利戈斯治疗公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-4240722-A1 | OXINDOLES AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022099066-A1 | OXINDOLES AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2781513-A1 | Benzofuran derivatives | Takeda Pharmaceutical Company Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| EP-2406243-B1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-05-07 | — | — | EP | disclosed |
| EP-1637527-B1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8288390-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-7507841-B2 | Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20090023800-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-01-22 | — | — | US | disclosed |
| US-7465815-B2 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20080021087-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-01-24 | — | — | US | disclosed |
| US-20070099990-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| EP-1637527-A1 | CANNABINOID RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2006-03-22 | — | — | EP | disclosed |
| EP-0413839-A1 | GHRH analogs | The Administrators of The Tulane Educational Fund (US) | 1991-02-27 | — | — | EP | disclosed |
| US-4914189-A | STIMULATES RELEASE OF GROWTH HORMONE | THE ADMINSTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1990-04-03 | — | — | US | disclosed |
| EP-0277626-A2 | Synthetic GHRH analogs | The Administrators of The Tulane Educational Fund (US) | 1988-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | AHR, BRPF3, CBR3 | ALDH1A1 618/4885KDM4E 1953/4885SMN1; SMN2 2846/4885 |
| US-20080021087-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | ALDH1A1 1463/4885KDM4E 737/4885SMN1; SMN2 4180/4885 |
| US-20090023800-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | ALDH1A1 1463/4885KDM4E 737/4885SMN1; SMN2 4180/4885 |
| US-20070099990-A1 | Cannabinoid receptor modulator | CNR1, CNR2, GPR18 | ALDH1A1 1463/4885KDM4E 737/4885SMN1; SMN2 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.